Effect of expanding opioid agonist therapies on the HIV epidemic and mortality in Ukraine: a modelling study.

Abstract:

BACKGROUND:As HIV incidence and mortality continue to increase in eastern Europe and central Asia, particularly among people who inject drugs (PWID), it is crucial to effectively scale-up opioid agonist therapy (OAT), such as methadone or buprenorphine maintenance therapy, to optimise HIV outcomes. With low OAT coverage among PWID, we did an optimisation assessment using current OAT procurement and allocation, then modelled the effect of increased OAT scale-up on HIV incidence and mortality for 23 administrative regions of Ukraine. METHODS:We developed a linear optimisation model to estimate efficiency gains that could be achieved based on current procurement of OAT. We also developed a dynamic, compartmental population model of HIV transmission that included both injection and sexual risk to estimate the effect of OAT scale-up on HIV infections and mortality over a 10-year horizon. The compartmental population model was calibrated to HIV prevalence and incidence among PWID for 23 administrative regions of Ukraine. Sources for regional data included the SyrEx database, the Integrated Biological and Behavioral Survey, the Ukrainian Center for Socially Dangerous Disease Control of the Ministry of Health of Ukraine, the Public Health Center of the Ministry of Health of Ukraine, and the Ukrainian Census. FINDINGS:Under a status-quo scenario (OAT coverage of 2·7% among PWID), the number of new HIV infections among PWID in Ukraine over the next 10 years was projected to increase to 58 820 (95% CI 47 968-65 535), with striking regional differences. With optimum allocation of OAT without additional increases in procurement, OAT coverage could increase from 2·7% to 3·3% by increasing OAT doses to ensure higher retention levels. OAT scale-up to 10% and 20% over 10 years would, respectively, prevent 4368 (95% CI 3134-5243) and 10 864 (7787-13 038) new HIV infections and reduce deaths by 7096 (95% CI 5078-9160) and 17 863 (12 828-23 062), relative to the status quo. OAT expansion to 20% in five regions of Ukraine with the highest HIV burden would account for 56% of new HIV infections and 49% of deaths prevented over 10 years. INTERPRETATION:To optimise HIV prevention and treatment goals in Ukraine, OAT must be substantially scaled up in all regions. Increased medication procurement is needed, combined with optimisation of OAT dosing. Restricting OAT scale-up to some regions of Ukraine could benefit many PWID, but the regions most affected are not necessarily those with the highest HIV burden. FUNDING:National Institute on Drug Abuse.

journal_name

Lancet HIV

journal_title

The lancet. HIV

authors

Tan J,Altice FL,Madden LM,Zelenev A

doi

10.1016/S2352-3018(19)30373-X

subject

Has Abstract

pub_date

2020-02-01 00:00:00

pages

e121-e128

issue

2

eissn

2405-4704

issn

2352-3018

pii

S2352-3018(19)30373-X

journal_volume

7

pub_type

杂志文章
  • Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.

    abstract:BACKGROUND:BMS-663068 is an oral prodrug of BMS-626529, an attachment inhibitor that binds to HIV-1 gp120, blocking viral attachment to host CD4 cells. AI438011 is an ongoing trial investigating the efficacy, safety, and dose-response of BMS-663068 in treatment-experienced, HIV-1-infected patients. Herein we present th...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/S2352-3018(15)00177-0

    authors: Lalezari JP,Latiff GH,Brinson C,Echevarría J,Treviño-Pérez S,Bogner JR,Thompson M,Fourie J,Sussmann Pena OA,Mendo Urbina FC,Martins M,Diaconescu IG,Stock DA,Joshi SR,Hanna GJ,Lataillade M,AI438011 study team.

    更新日期:2015-10-01 00:00:00

  • Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppr

    abstract:BACKGROUND:Simplified regimens with reduced pill burden and fewer side-effects are desirable for people living with HIV. We investigated the efficacy and safety of switching to a single-tablet regimen of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide versus continuing a regimen of boosted protease inhi...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/S2352-3018(17)30179-0

    authors: Orkin C,Molina JM,Negredo E,Arribas JR,Gathe J,Eron JJ,Van Landuyt E,Lathouwers E,Hufkens V,Petrovic R,Vanveggel S,Opsomer M,EMERALD study group.

    更新日期:2018-01-01 00:00:00

  • Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.

    abstract:BACKGROUND:Although antiretroviral regimens containing integrase inhibitors rapidly suppress HIV viral load in non-pregnant adults, few published data from randomised controlled trials have compared the safety and efficacy of any integrase inhibitor to efavirenz when initiated during pregnancy. We compared safety and e...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/S2352-3018(20)30038-2

    authors: João EC,Morrison RL,Shapiro DE,Chakhtoura N,Gouvèa MIS,de Lourdes B Teixeira M,Fuller TL,Mmbaga BT,Ngocho JS,Njau BN,Violari A,Mathiba R,Essack Z,Pilotto JHS,Moreira LF,Rolon MJ,Cahn P,Prommas S,Cressey TR,Chokephai

    更新日期:2020-05-01 00:00:00

  • PrEP for key populations in combination HIV prevention in Nairobi: a mathematical modelling study.

    abstract:BACKGROUND:The HIV epidemic in the population of Nairobi as a whole is in decline, but a concentrated sub-epidemic persists in key populations. We aimed to identify an optimal portfolio of interventions to reduce HIV incidence for a given budget and to identify the circumstances in which pre-exposure prophylaxis (PrEP)...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(17)30021-8

    authors: Cremin I,McKinnon L,Kimani J,Cherutich P,Gakii G,Muriuki F,Kripke K,Hecht R,Kiragu M,Smith J,Hinsley W,Gelmon L,Hallett TB

    更新日期:2017-05-01 00:00:00

  • Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis.

    abstract:BACKGROUND:With continued roll-out of antiretroviral therapy (ART) in resource-limited settings, evidence is emerging of increasing levels of transmitted drug-resistant HIV. We aimed to compare the effectiveness and cost-effectiveness of different potential public health responses to substantial levels of transmitted d...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(14)70021-9

    authors: Phillips AN,Cambiano V,Miners A,Revill P,Pillay D,Lundgren JD,Bennett D,Raizes E,Nakagawa F,De Luca A,Vitoria M,Barcarolo J,Perriens J,Jordan MR,Bertagnolio S

    更新日期:2014-11-01 00:00:00

  • Catalysing the development and introduction of paediatric drug formulations for children living with HIV: a new global collaborative framework for action.

    abstract::Progress in the development and introduction of paediatric formulations for key infectious diseases is poor in low-income and middle-income countries (LMICs). Although major steps have been made in the scale-up of antiretroviral medicines in LMICs, the development and deployment of formulations for infants and childre...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(18)30005-5

    authors: Penazzato M,Watkins M,Morin S,Lewis L,Pascual F,Vicari M,Lee J,Hargreaves S,Doherty M,Siberry GK

    更新日期:2018-05-01 00:00:00

  • Issues about periconception use of dolutegravir are reminiscent of early concerns about efavirenz.

    abstract::South Africa intends to include dolutegravir in its first-line antiretroviral therapy (ART) regimen because of cost savings, the drug's high barrier to resistance, and efficacy. However, recent data from Botswana suggest potential teratogenicity of dolutegravir. WHO recommends that non-pregnant women of childbearing a...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(18)30249-2

    authors: Black V,Schwartz SR

    更新日期:2018-12-01 00:00:00

  • Home testing and counselling to reduce HIV incidence in a generalised epidemic setting: a mathematical modelling analysis.

    abstract:BACKGROUND:Home HIV testing and counselling (HTC) achieves high levels of HIV testing and linkage to care. Periodic home HTC, particularly targeted to those with high HIV viral load, might facilitate expansion of antiretroviral therapy (ART) coverage. We used a mathematical model to assess the effect of periodic home H...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(16)30009-1

    authors: Ying R,Sharma M,Celum C,Baeten JM,van Rooyen H,Hughes JP,Garnett G,Barnabas RV

    更新日期:2016-06-01 00:00:00

  • Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.

    abstract:BACKGROUND:All recent treatment guidelines recommend integrase strand transfer inhibitors (INSTIs) as components of initial HIV therapy. Bictegravir, a novel, once-daily, unboosted INSTI, showed potent activity in a 10 day monotherapy study and has a high in-vitro resistance barrier. On the basis of these results, we d...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/S2352-3018(17)30016-4

    authors: Sax PE,DeJesus E,Crofoot G,Ward D,Benson P,Dretler R,Mills A,Brinson C,Peloquin J,Wei X,White K,Cheng A,Martin H,Quirk E

    更新日期:2017-04-01 00:00:00

  • Community-based HIV prevalence in KwaZulu-Natal, South Africa: results of a cross-sectional household survey.

    abstract:BACKGROUND:In high HIV burden settings, maximising the coverage of prevention strategies is crucial to achieving epidemic control. However, little is known about the reach and effect of these strategies in some communities. METHODS:We did a cross-sectional community survey in the adjacent Greater Edendale and Vulindle...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(18)30104-8

    authors: Kharsany ABM,Cawood C,Khanyile D,Lewis L,Grobler A,Puren A,Govender K,George G,Beckett S,Samsunder N,Madurai S,Toledo C,Chipeta Z,Glenshaw M,Hersey S,Abdool Karim Q

    更新日期:2018-08-01 00:00:00

  • Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data.

    abstract:BACKGROUND:Isoniazid preventive therapy prevents active tuberculosis in people with HIV, but previous studies have found no evidence of benefit in people with HIV who had a negative tuberculin skin test, and a non-significant effect on mortality. We aimed to estimate the effect of isoniazid preventive therapy given wit...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,meta分析

    doi:10.1016/S2352-3018(20)30299-X

    authors: Ross JM,Badje A,Rangaka MX,Walker AS,Shapiro AE,Thomas KK,Anglaret X,Eholie S,Gabillard D,Boulle A,Maartens G,Wilkinson RJ,Ford N,Golub JE,Williams BG,Barnabas RV

    更新日期:2021-01-01 00:00:00

  • Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions.

    abstract::The evaluation of immune-based approaches to achieve an antiretroviral therapy free remission of HIV infection requires proven efficacy through antiretroviral therapy interruption placebo-controlled trials. This approach is not without risk to participants and innovative trial designs need to be developed that minimis...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,评审

    doi:10.1016/S2352-3018(19)30082-7

    authors: Moore CL,Stöhr W,Crook AM,Richert L,Leliévre JD,Pantaleo G,García F,Vella S,Lévy Y,Thiébaut R,McCormack S

    更新日期:2019-05-01 00:00:00

  • Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis.

    abstract:BACKGROUND:Although lifelong combination antiretroviral therapy (ART) is recommended for all individuals with HIV, few data exist for pregnancy outcomes associated with ART initiation before conception. We assessed adverse pregnancy outcomes associated with ART initiated before conception compared with that of ART star...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/S2352-3018(16)30195-3

    authors: Uthman OA,Nachega JB,Anderson J,Kanters S,Mills EJ,Renaud F,Essajee S,Doherty MC,Mofenson LM

    更新日期:2017-01-01 00:00:00

  • Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, ph

    abstract:BACKGROUND:Switching from therapy based on a boosted protease inhibitor to bictegravir, emtricitabine, and tenofovir alafenamide could avoid drug interactions and unwanted side-effects in virologically suppressed adults with HIV-1 infection, while maintaining a high barrier to resistance and providing a simplified once...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/S2352-3018(18)30091-2

    authors: Daar ES,DeJesus E,Ruane P,Crofoot G,Oguchi G,Creticos C,Rockstroh JK,Molina JM,Koenig E,Liu YP,Custodio J,Andreatta K,Graham H,Cheng A,Martin H,Quirk E

    更新日期:2018-07-01 00:00:00

  • From HIV infection to therapeutic response: a population-based longitudinal HIV cascade-of-care study in KwaZulu-Natal, South Africa.

    abstract:BACKGROUND:Standard approaches to estimation of losses in the HIV cascade of care are typically cross-sectional and do not include the population stages before linkage to clinical care. We used indiviual-level longitudinal cascade data, transition by transition, including population stages, both to identify the health-...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(16)30224-7

    authors: Haber N,Tanser F,Bor J,Naidu K,Mutevedzi T,Herbst K,Porter K,Pillay D,Bärnighausen T

    更新日期:2017-05-01 00:00:00

  • Near real-time monitoring of HIV transmission hotspots from routine HIV genotyping: an implementation case study.

    abstract:BACKGROUND:HIV evolves rapidly and therefore infections with similar genetic sequences are likely linked by recent transmission events. Clusters of related infections can represent subpopulations with high rates of transmission. We describe the implementation of an automated near real-time system to monitor and charact...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(16)00046-1

    authors: Poon AF,Gustafson R,Daly P,Zerr L,Demlow SE,Wong J,Woods CK,Hogg RS,Krajden M,Moore D,Kendall P,Montaner JS,Harrigan PR

    更新日期:2016-05-01 00:00:00

  • Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list.

    abstract::Despite considerable progress in paediatric HIV treatment and timely revision of global policies recommending the use of more effective and tolerable antiretroviral regimens, optimal antiretroviral formulations for infants, children, and adolescents remain limited. The Paediatric Antiretroviral Drug Optimization group...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,评审

    doi:10.1016/S2352-3018(19)30193-6

    authors: Penazzato M,Townsend CL,Rakhmanina N,Cheng Y,Archary M,Cressey TR,Kim MH,Musiime V,Turkova A,Ruel TD,Rabie H,Sugandhi N,Rojo P,Doherty M,Abrams EJ,PADO4 participants.

    更新日期:2019-09-01 00:00:00

  • Conditional cash transfers and uptake of and retention in prevention of mother-to-child HIV transmission care: a randomised controlled trial.

    abstract:BACKGROUND:Novel strategies are needed to increase retention in and uptake of prevention of mother-to-child HIV transmission (PMTCT) services in sub-Saharan Africa. We aimed to determine whether small, increasing cash payments, which were conditional on attendance at scheduled clinic visits and receipt of proposed serv...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/S2352-3018(15)00247-7

    authors: Yotebieng M,Thirumurthy H,Moracco KE,Kawende B,Chalachala JL,Wenzi LK,Ravelomanana NL,Edmonds A,Thompson D,Okitolonda EW,Behets F

    更新日期:2016-02-01 00:00:00

  • A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of a Chemokine Receptor 5 (CCR5) Antagonist to Decrease the Occurrence of Immune Reconstitution Inflammatory Syndrome in HIV-Infection: The CADIRIS Study.

    abstract:BACKGROUND:Immune Reconstitution Inflammatory Syndrome (IRIS) is a common complication of antiretroviral therapy (ART) in HIV-infected patients. IRIS is associated with an increased risk of hospitalization and death. We ascertained whether CCR5 blockade using maraviroc reduces the risk of IRIS. METHODS:The CADIRIS stu...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(14)70027-X

    authors: Sierra-Madero JG,Ellenberg S,Rassool MS,Tierney A,Belaunzarán-Zamudio PF,López-Martínez A,Piñeirúa-Menéndez A,Montaner LJ,Azzoni L,Benítez CR,Sereti I,Andrade-Villanueva J,Mosqueda-Gómez JL,Rodriguez B,Sanne I,Lederman MM,

    更新日期:2014-11-01 00:00:00

  • Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial.

    abstract:BACKGROUND:Universal antiretroviral therapy (ART), as per the 2015 WHO recommendations, might reduce population HIV incidence. We investigated the effect of universal test and treat on HIV acquisition at population level in a high prevalence rural region of South Africa. METHODS:We did a phase 4, open-label, cluster r...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/S2352-3018(17)30205-9

    authors: Iwuji CC,Orne-Gliemann J,Larmarange J,Balestre E,Thiebaut R,Tanser F,Okesola N,Makowa T,Dreyer J,Herbst K,McGrath N,Bärnighausen T,Boyer S,De Oliveira T,Rekacewicz C,Bazin B,Newell ML,Pillay D,Dabis F,ANRS 12249 Tas

    更新日期:2018-03-01 00:00:00

  • Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study.

    abstract:BACKGROUND:Measures of CD4 T-cell count and HIV-1 plasma viral load before antiretroviral therapy are proxies for virulence. Whether these proxies are changing over time has implications for prevention and treatment. The aim of this study was to investigate those trends. METHODS:Data were derived from the Concerted Ac...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(14)00002-2

    authors: Pantazis N,Porter K,Costagliola D,De Luca A,Ghosn J,Guiguet M,Johnson AM,Kelleher AD,Morrison C,Thiebaut R,Wittkop L,Touloumi G,CASCADE Collaboration in EuroCoord.

    更新日期:2014-12-01 00:00:00

  • Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

    abstract:BACKGROUND:Bictegravir co-formulated with emtricitabine and tenofovir alafenamide as a fixed-dose combination is recommended for treatment of HIV-1-infection and might be better tolerated than other integrase inhibitor-based single-tablet regimens, but long-term outcomes data are not available. We assessed the efficacy...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/S2352-3018(19)30077-3

    authors: Wohl DA,Yazdanpanah Y,Baumgarten A,Clarke A,Thompson MA,Brinson C,Hagins D,Ramgopal MN,Antinori A,Wei X,Acosta R,Collins SE,Brainard D,Martin H

    更新日期:2019-06-01 00:00:00

  • CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.

    abstract:BACKGROUND:In patients with HIV, immune reconstitution after antiretroviral therapy (ART) is often incomplete. We assessed the probability of patients reaching a CD4/CD8 ratio of 1 or more after the start of ART and its association with the onset of non-AIDS-defining events and death. METHODS:We did an analysis of the...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(15)00006-5

    authors: Mussini C,Lorenzini P,Cozzi-Lepri A,Lapadula G,Marchetti G,Nicastri E,Cingolani A,Lichtner M,Antinori A,Gori A,d'Arminio Monforte A,Icona Foundation Study Group.

    更新日期:2015-03-01 00:00:00

  • Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.

    abstract:BACKGROUND:Modest efficacy was reported for the HIV vaccine tested in the RV144 trial, which comprised a canarypox vector (ALVAC) and envelope (env) glycoprotein (gp120). These vaccine components were adapted to express HIV-1 antigens from strains circulating in South Africa, and the adjuvant was changed to increase im...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/S2352-3018(18)30071-7

    authors: Bekker LG,Moodie Z,Grunenberg N,Laher F,Tomaras GD,Cohen KW,Allen M,Malahleha M,Mngadi K,Daniels B,Innes C,Bentley C,Frahm N,Morris DE,Morris L,Mkhize NN,Montefiori DC,Sarzotti-Kelsoe M,Grant S,Yu C,Mehra VL,Pen

    更新日期:2018-07-01 00:00:00

  • Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial.

    abstract:BACKGROUND:An intravaginal ring that releases the tenofovir prodrug, tenofovir disoproxil fumarate, provided 100% protection in macaques against simian HIV and was safe in a 14-day clinical trial in sexually abstinent women. We aimed to assess the safety and pharmacokinetics of this intravaginal ring over 90 days in se...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/S2352-3018(19)30145-6

    authors: Keller MJ,Wood L,Billingsley JM,Ray LL,Goymer J,Sinclair S,McGinn AP,Marzinke MA,Frank B,Srinivasan S,Liu C,Atrio JM,Espinoza L,Mugo N,Spiegel HML,Anderson PL,Fredricks DN,Hendrix CW,Marrazzo J,Bosinger SE,Herold

    更新日期:2019-08-01 00:00:00

  • Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, n

    abstract:BACKGROUND:ADVANCE compared the efficacy and safety of two antiretroviral first-line combinations (dolutegravir combined with emtricitabine and either tenofovir disoproxil fumarate or tenofovir alafenamide), with a third regimen (efavirenz combined with emtricitabine and tenofovir disoproxil fumarate) previously recomm...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/S2352-3018(20)30241-1

    authors: Venter WDF,Sokhela S,Simmons B,Moorhouse M,Fairlie L,Mashabane N,Serenata C,Akpomiemie G,Masenya M,Qavi A,Chandiwana N,McCann K,Norris S,Chersich M,Maartens G,Lalla-Edward S,Vos A,Clayden P,Abrams E,Arulappan N,Hi

    更新日期:2020-10-01 00:00:00

  • Ending the HIV epidemic in the USA: an economic modelling study in six cities.

    abstract:BACKGROUND:The HIV epidemic in the USA is a collection of diverse local microepidemics. We aimed to identify optimal combination implementation strategies of evidence-based interventions to reach 90% reduction of incidence in 10 years, in six US cities that comprise 24·1% of people living with HIV in the USA. METHODS:...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(20)30033-3

    authors: Nosyk B,Zang X,Krebs E,Enns B,Min JE,Behrends CN,Del Rio C,Dombrowski JC,Feaster DJ,Golden M,Marshall BDL,Mehta SH,Metsch LR,Pandya A,Schackman BR,Shoptaw S,Strathdee SA,Localized HIV Modeling Study Group.

    更新日期:2020-07-01 00:00:00

  • PrEP awareness and engagement among transgender women in South Africa: a cross-sectional, mixed methods study.

    abstract:BACKGROUND:The South African national HIV plan recommends pre-exposure prophylaxis (PrEP) for transgender women, whose HIV prevalence estimates are as high as 25% in sub-Saharan Africa. The aim of this study was to explore PrEP awareness, uptake, and willingness, as well as associated barriers and facilitators, in orde...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(20)30119-3

    authors: Poteat T,Malik M,van der Merwe LLA,Cloete A,Adams D,Nonyane BAS,Wirtz AL

    更新日期:2020-12-01 00:00:00

  • Enhanced immigration enforcement in the USA and the transnational continuity of HIV care for Latin American immigrants in deportation proceedings.

    abstract::In our work as clinicians, researchers, and immigrant rights advocates, we have noted increased anxiety about the possibility of deportation and disruptions in care among immigrants with HIV. Before the 2016 US elections, patients rarely asked about HIV treatment in their home countries. However, since the increase in...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(18)30074-2

    authors: Page KR,Grieb SD,Nieves-Lugo K,Yamanis T,Taylor H,Martinez O,Yamasaki Y,Limaye R,Davis W,Beyrer C,Zea MC

    更新日期:2018-10-01 00:00:00

  • Unveiling of HIV dynamics among transgender women: a respondent-driven sampling study in Rio de Janeiro, Brazil.

    abstract:BACKGROUND:The burden of HIV in transgender women (transwomen) in Brazil remains unknown. We aimed to estimate HIV prevalence among transwomen in Rio de Janeiro and to identify predictors of newly diagnosed HIV infections. METHODS:We recruited transwomen from Rio de Janeiro, Brazil, by respondent-driven sampling. Elig...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(17)30015-2

    authors: Grinsztejn B,Jalil EM,Monteiro L,Velasque L,Moreira RI,Garcia AC,Castro CV,Krüger A,Luz PM,Liu AY,McFarland W,Buchbinder S,Veloso VG,Wilson EC,Transcender Study Team.

    更新日期:2017-04-01 00:00:00